Case guide

What Does Long Use of Depo-Provera Mean for Me?

Used the shot for years? The label warns about tumors after repeat use.

See If You Qualify

Free · No obligation · About 2 minutes

Updated Oct 4, 202616 sources

This may apply to you if

  • Have your shot name and dates ready for a lawyer to review.
  • Have the report that names your meningioma, a tumor in tissue around the brain.
  • If you already have a lawyer, ask whether your claim is eligible for the reported program.

What the public record says

These are cited sources. Their inclusion does not imply that they endorse People’s Justice or reviewed this page.

M. Casey Rodgers · U.S. District Court, Northern District of Florida · United States District Judge

Finding: The August 10, 2026 order describes an agreement for many existing federal claims and separate court procedures for continuing litigation. Ask a lawyer which track applies to you.

Case Management Order No. 14 (opens in a new tab) · Aug 10, 2026 · Checked Oct 3, 2026

Noémie Roland · EPI-PHARE, French National Agency for Medicines and Health Products Safety and French National Health Insurance · First-listed study author

Finding: The 2024 BMJ study found an association between injectable medroxyprogesterone use and meningioma surgery in French health records. A small exposed group and observational design limit what it can show about an individual.

Use of progestogens and the risk of intracranial meningioma: national case-control study (opens in a new tab) · Mar 27, 2024 · Checked Oct 3, 2026

The evidence and its limits

EPI-PHARE · BMJ · 2024

French health-record study of hormone medicines and meningioma surgery

Design:
Case-control
Participants:
108,366 women: 18,061 surgery cases and 90,305 matched controls
Finding:
Injectable medroxyprogesterone acetate use was associated with higher odds of surgery for meningioma; the excess was linked to prolonged use.
Main limitation
Observational French data; only nine exposed cases and eleven exposed controls for this injection. The study does not prove that the shot caused any one person’s tumor or define who qualifies for a claim.

Read the source: French health-record study of hormone medicines and meningioma surgery (opens in a new tab) · Checked Oct 3, 2026

The short answer

What does the long-term warning say?
The label warns about tumors called meningiomas after repeat use. They grow in tissue around the brain or spine. Ask your doctor what this means for you. [3]
Did the study prove the shot caused every tumor?
No. The French study compared health records and found an association. That design does not identify the cause of one person’s illness. [9]
Does longer use decide whether I have a claim?
Use length is a fact to document, not a result this page can assign. Ask a lawyer to compare your product and diagnosis records with the rules for your case. [1]
How can I rebuild dates from old records?
List the clinics that gave the shots and the years you remember. Ask each provider how to get records that are still held. Mark gaps instead of turning guesses into dates. [6]

What rules a case out

Not covered by this case

  • The study’s use groups are not settlement eligibility rules.
  • Years of use alone do not identify the cause of a tumor.
  • A claim guide does not choose your next medicine or scan.

The process

What happens next

  1. 01

    You answer a few questions

    About two minutes. Nothing is sent until you agree on the last step and press submit.

  2. 02

    A lawyer looks at it

    A lawyer at the firm reads your answers and checks them against the current case criteria.

  3. 03

    The firm decides and gets in touch

    If the firm takes your case, you get the terms in writing to read before you sign. You can always say no.

Used the shot for years? The label warns about tumors after repeat use. Ask your clinician about your care and a lawyer about your own records.

What does the long-term warning say?

The label warns about tumors called meningiomas after repeat use. They grow in tissue around the brain or spine. Ask your doctor what this means for you.

The December 2025 label tells clinicians to watch for signs and symptoms. If a meningioma is diagnosed, it directs them to stop the medicine. Contact your care team to plan the next step rather than use a lawsuit page to manage care.

Did the study prove the shot caused every tumor?

No. The French study compared health records and found an association. That design does not identify the cause of one person’s illness.

The researchers studied women who had surgery for a meningioma and matched women without that surgery. Only nine surgery cases and eleven controls had the injection exposure studied. A large total sample does not remove that small-group limit.

The outcome was surgery for an intracranial tumor. It was not every tumor diagnosis, every person who used the shot, or a measure of a U.S. user’s chance of illness.

Does longer use decide whether I have a claim?

Use length is a fact to document, not a result this page can assign. Ask a lawyer to compare your product and diagnosis records with the rules for your case.

The court describes claims involving alleged intracranial meningiomas after product use. Its program and continuing-case routes are separate. A research exposure group does not replace either legal review.

How can I rebuild dates from old records?

List the clinics that gave the shots and the years you remember. Ask each provider how to get records that are still held. Mark gaps instead of turning guesses into dates.

Federal access rules generally allow an individual to request covered health records, with exceptions. The right concerns records that the provider maintains. It does not promise that every old injection record still exists.

Make a separate list of the dates of scans, diagnosis and treatment. Keep a copy of the reports if you have them. Ask your clinician what the tumor record actually says.

What should I ask before another appointment?

Bring your medicine history and the question you want answered. Ask what the warning means for your care, whether tests are needed and what alternatives fit your health.

The warning directs clinical monitoring; it is not a scan schedule for every former user. A treating clinician should decide your evaluation and medication plan. Legal program registration is a different task.

If you also want a claim review, ask who will handle it and what it costs. Ask for your personal filing deadline rather than counting years from an internet rule.

Scientific evidence for this case

Find out where you stand.

The review is free and private. Asking for it doesn’t commit you to anything.

Register your interest

Questions about this guide

I used Depo-Provera for 10 years. What is my risk?

It depends. Ask your treating clinician about symptoms, testing, or medication changes. The FDA label says to monitor for signs and symptoms of meningioma and to discontinue Depo-Provera CI if a meningioma is diagnosed. A claim page cannot diagnose you or decide your medical care.

Source: FDA Depo-Provera CI label, revised December 2025 · as of Oct 7, 2026

Why didn't my doctor warn me about the brain tumor risk?

Ask your treating clinician about symptoms, testing, or medication changes. The FDA label says to monitor for signs and symptoms of meningioma and to discontinue Depo-Provera CI if a meningioma is diagnosed. A claim page cannot diagnose you or decide your medical care.

Source: FDA Depo-Provera CI label, revised December 2025 · as of Oct 7, 2026

Can I recover damages for bone density loss too?

Potentially. If you suffered bone density loss alongside a meningioma, both injuries can be included in your claim. However, the bone density risk was disclosed via the 2004 black box warning, making the failure-to-warn argument stronger for meningioma (which had no U.S. warning until December 2025).

Sources

  1. Court order 14: settlement and ongoing casesCourt order 14: settlement and ongoing cases · court
  2. JPML pending cases report, October 1, 2026JPML pending cases report, October 1, 2026 · court
  3. FDA Depo-Provera CI label, December 2025FDA Depo-Provera CI label, December 2025 · regulator
  4. National Cancer Institute: meningiomaNational Cancer Institute: meningioma · regulator
  5. ABA Model Rule 1.5: feesABA Model Rule 1.5: fees
  6. Medical record access: 45 CFR 164.524Medical record access: 45 CFR 164.524 · regulator
  7. SDNY court guide: filing time limitsSDNY court guide: filing time limits · court
  8. Court common-benefit fee order 2Court common-benefit fee order 2 · court
  9. BMJ 2024 original author abstract via PubMedBMJ 2024 original author abstract via PubMed · study
  10. Medroxyprogesterone Acetate and Meningioma: A Global IssueFrontiers in Global Womens Health · 2025 · study
  11. Use of High-Dose Medroxyprogesterone Acetate and Risk of Intracranial MeningiomaThe BMJ · 2024 · study
  12. The Association between Medroxyprogesterone Acetate Exposure and MeningiomaCancers · 2024 · study
  13. Pfizer Reaches Agreement in Principle to Resolve Federal Depo-Provera MDLlaw360.com · Jun 15, 2026 · court
  14. JAMA Network Open Study Reports 4.5x Meningioma Risk with Medroxyprogesteronepubmed.ncbi.nlm.nih.gov · Jul 1, 2026 · study
  15. On June 15, 2026, MDL 3140 (N.D. Fla.) Leadership Counsel announced a settlement with the Pfizer defendants of a majority of the claims in the MDL and New York state court over Depo-Provera meningioma claims (Case Management Order No. 12, filed July 27, 2026). Financial terms NOT disclosed; eligibility and compensation amounts not released; deal pending finalization at the time (Case Management Order No. 14, filed Aug. 10, 2026, later described a settlement agreement dated July 22, 2026 and states no compensation amounts). The JPML reported 5,830 actions pending in MDL 3140 on July 1, 2026 and 6,412 on October 1, 2026.flnd.uscourts.gov · Jun 15, 2026 · court
  16. Settlement in principle announced; docket had grown +1,739 filings (+46%) in the single preceding month — the leading-indicator pattern.jpml.uscourts.gov · Jun 15, 2026 · court

Checked against 14 primary sources by People's Justice editors · Updated

How we make money

People's Justice research team · Updated Oct 4, 2026